Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs

Circulation

Volumn 117, Issue 19, 2008, Pages 2449-2457

  Li, Gui Rong ^a,d   Wang, Hong Bing ^b   Qin, Guo Wei ^b   Jin, Man Wen ^c   Tang, Qiang ^c   Sun, Hai Ying ^a   Du, Xin Ling ^a   Deng, Xiu Ling ^a   Zhang, Xiao Hua ^c   Chen, Jing Bo ^c   Chen, Lei ^c   Xu, Xiao Hui ^c   Cheng, Lik Cheung ^d   Chiu, Shui Wah ^d   Tse, Hung Fat ^a   Vanhoutte, Paul M ^a   Lau, Chu Pak ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Arrhythmia; Drugs; Electrophysiology; Ion channels; Pharmacology

Indexed keywords

ACACETIN; ACETYLCHOLINE; CALCIUM CHANNEL L TYPE; DELAYED RECTIFIER POTASSIUM CHANNEL; FLAVONE DERIVATIVE; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ1; SOTALOL;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CURRENT; CELL LINE; CELL STRAIN HEK293; CHINESE MEDICINE; CONTROLLED STUDY; DOG; DRUG SELECTIVITY; EMBRYO; FEMALE; GUINEA PIG; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART LEFT ATRIUM; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; HEART RIGHT ATRIUM; HUMAN; HUMAN CELL; IC 50; ION CURRENT; MALE; MEDICINAL PLANT; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT INTERVAL; RABBIT; SAUSSUREA TRIDACTYLA; SODIUM CURRENT; WHOLE CELL;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FUNCTION; CELLS, CULTURED; FLAVONES; GUINEA PIGS; HUMANS; MEDICINE, CHINESE TRADITIONAL; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; POTASSIUM;

EID: 43449090419     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.769554     Document Type: Article

References (46)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
2. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920-2925.
3. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-1046.
4. Lip GY, Tse HF. Management of atrial fibrillation. Lancet. 2007;370:604-618.
5. Nademanee K. The amiodarone odyssey. J Am Coll Cardiol. 1992;20:1063-1065.
6. Roden DM. Current status of class III antiarrhythmic drug therapy. Am J Cardiol. 1993;72:44B-49B.
7. Roden DM, Anderson ME. Proarrhythmia. Handb Exp Pharmacol. 2006;73-97.
8. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116:1449-1457.
9. Blaauw Y, Gogelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation. 2004;110:1717-1724.
10. + current in human ventricular myocytes. Circ Res. 1996;78:689-696.
11. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol. 1999;84:11R-19R.
12. Pirard B, Brendel J, Peukert S. The discovery of Kv1.5 blockers as a case study for the application of virtual screening approaches. J Chem Inf Model. 2005;45:477-485.
13. + current by verapamil in human atrial myocytes. J Mol Cell Cardiol. 2004;36:257-263.
14. Li GR, Lau CP, Shrier A. Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. J Mol Cell Cardiol. 2002;34:1185-1194.
15. Tang Q, Jin MW, Xiang JZ, Dong MQ, Sun HY, Lau CP, Li GR. The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go related gene potassium channels stably expressed in HEK 293 cells. Biochem Pharmacol. 2007;74:1596-1607.
16. Dong MQ, Lau CP, Gao Z, Tseng GN, Li GR. Characterization of recombinant human cardiac KCNQ1/KCNE1 channels (I(Ks)) stably expressed in HEK 293 cells. J Membr Biol. 2006;210:183-192.
17. + current in guinea pig cardiac myocytes. Am J Physiol Heart Circ Physiol. 2000;279:H130-H138.
18. K of rabbit ventricle is composed of two currents: evidence for IKs. Am J Physiol. 1996;271:H2477-H2489.
19. Milberg P, Ramtin S, Monnig G, Osada N, Wasmer K, Breithardt G, Haverkamp W, Eckardt L. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. J Cardiovasc Pharmacol. 2004;44:278-286.
20. Cody V. Crystal and molecular structures of flavonoids. Prog Clin Biol Res. 1988;280:29-44.
21. Liao YH, Houghton PJ, Hoult JR. Novel and known constituents from Buddleja species and their activity against leukocyte eicosanoid generation. J Nat Prod. 1999;62:1241-1245.
22. Kraft C, Jenett-Siems K, Siems K, Jakupovic J, Mavi S, Bienzle U, Eich E. In vitro antiplasmodial evaluation of medicinal plants from Zimbabwe. Phytother Res. 2003;17:123-128.
23. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M, Koizumi M, Ito C, Furukawa H. Quantitative study of flavonoids in leaves of citrus plants. J Agric Food Chem. 2000;48:3865-3871.
24. Singh RP, Agrawal P, Yim D, Agarwal C, Agarwal R. Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: structure-activity relationship with linarin and linarin acetate. Carcinogenesis. 2005;26:845-854.
25. Pan MH, Lai CS, Wang YJ, Ho CT. Acacetin suppressed LPS-induced up-expression of iNOS and COX-2 in murine macrophages and TPA-induced tumor promotion in mice. Biochem Pharmacol. 2006;72:1293-1303.
26. Hsu YL, Kuo PL, Lin CC. Acacetin inhibits the proliferation of Hep G2 by blocking cell cycle progression and inducing apoptosis. Biochem Pharmacol. 2004;67:823- 829.
27. Zhang K, Yang EB, Tang WY, Wang KP, Mack P. Inhibition of glutathione reductase by plant polyphenols. Biochem Pharmacol. 1997;54:1047-1053.
28. Doostdar H, Burke MD, Mayer RT. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology. 2000;144:31-38.
29. Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res. 1999;42:477-489.
30. Nattel S, Khairy P, Roy D, Thibault B, Guerra P, Talajic M, Dubuc M. New approaches to atrial fibrillation management: a critical review of a rapidly evolving field. Drugs. 2002;62:2377-2397.
31. Cholbi MR, Paya M, Alcaraz MJ. Inhibitory effects of phenolic compounds on CCl4-induced microsomal lipid peroxidation. Experientia. 1991;47:195-199.
32. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation. 2004;110:2299-2306.
33. Schauerte P, Scherlag BJ, Pitha J, Scherlag MA, Reynolds D, Lazzara R, Jackman WM. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation. 2000;102:2774-2780.
34. Zipes DP, Mihalick MJ, Robbins GT. Effects of selective vagal and stellate ganglion stimulation of atrial refractoriness. Cardiovasc Res. 1974;8:647-655.
35. KACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res. 2006;54:136-141.
36. Liu L, Nattel S. Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol. 1997;273:H805-H816.
37. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res. 1999;44:121-131.
38. + channels in canine atria with atrial fibrillation induced by experimental congestive heart failure. Cell Physiol Biochem. 2004;14:31-40.
39. Pecini R, Elming H, Pedersen OD, Torp-Pedersen C. New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005;10:311-322.
40. Seki A, Hagiwara N, Kasanuki H. Effects of NIP-141 on K currents in human atrial myocytes. J Cardiovasc Pharmacol. 2002;39:29-38.
41. Kur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation. 2006;114:1234-1242.
42. Gogelein H, Brendel J, Steinmeyer K, Strubing C, Picard N, Rampe D, Kopp K, Busch AE, Bleich M. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:183-192.
43. Fedida D, Orth PM, Chen JY, Lin S, Plouvier B, Jung G, Ezrin AM, Beatch GN. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16:1227-1238.
44. Kur blocker, (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate. J Pharmacol Exp Ther. 2006;316:727-732.
45. Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res. 2005;97:629-636.
46. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104:174-180.